NASDAQ:DXCM - DexCom Stock Price, Forecast & News

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings results on Thursday, February, 13th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.41. The medical device company earned $462.80 million during the quarter, compared to analyst estimates of $457 million. View DexCom's Earnings History.

DexCom is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for DexCom.

DexCom updated its FY 2020 After-Hours earnings guidance on Thursday, February, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.725-1.775 billion, compared to the consensus revenue estimate of $1.77 billion.

18 analysts have issued 1 year price objectives for DexCom's stock. Their forecasts range from $125.00 to $300.00. On average, they expect DexCom's stock price to reach $256.72 in the next year. This suggests that the stock has a possible downside of 9.6%. View Analyst Price Targets for DexCom.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

News coverage about DXCM stock has trended somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. DexCom earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for DexCom.

DexCom saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 4,750,000 shares, a drop of 5.4% from the January 15th total of 5,020,000 shares. Based on an average daily volume of 986,900 shares, the days-to-cover ratio is currently 4.8 days. Currently, 5.3% of the company's shares are sold short. View DexCom's Current Options Chain.

Some companies that are related to DexCom include Abbott Laboratories (ABT), ABIOMED (ABMD), CONMED (CNMD), ProShares UltraShort DJ-UBS Commodity (CMD), Synthorx (THOR), AtriCure (ATRC), AngioDynamics (ANGO), Alphatec (ATEC), Accuray (ARAY), Fc Global Realty (FCRE), Navidea Biopharmaceuticals (NAVB), Baxter International (BAX), Becton Dickinson and (BDX), Boston Scientific (BSX) and Cardiovascular Systems (CSII).

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM), Netflix (NFLX), ServiceNow (NOW), Home Depot (HD), Micron Technology (MU), Adobe (ADBE) and Veeva Systems (VEEV).

DexCom's stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (5.26%), Jennison Associates LLC (3.78%), Artisan Partners Limited Partnership (2.06%), Blair William & Co. IL (1.32%), Fred Alger Management LLC (0.82%) and Renaissance Technologies LLC (0.77%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Victory Capital Management Inc., Victory Capital Management Inc., Peregrine Capital Management LLC, Columbus Circle Investors, First Trust Advisors LP, Point72 Asset Management L.P. and Artisan Partners Limited Partnership. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Fred Alger Management LLC, Beacon Investment Advisory Services Inc., Lord Abbett & CO. LLC, Kornitzer Capital Management Inc. KS, Cubist Systematic Strategies LLC, Blair William & Co. IL and Goldman Sachs Group Inc.. View Insider Buying and Selling for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $283.91.